What is mild cognitive impairment? Mild cognitive impairment (MCI) is an early stage of memory loss or other cognitive ability loss in individuals who maintain the ability to independently perform most activities of daily living. Learn More How do I receive the Biogen treatment? If you or a loved one is experiencing memory changes, the Alzheimer’s Association strongly encourages speaking with a health care provider for a thorough evaluation and diagnosis. Aducanumab may be a treatment option. How is this drug administered? Aducanumab is administered intravenously (IV) via a 45- to 60-minute infusion every 4 weeks. Infusion can be done at hospitals or infusion therapy centers, and can even be administered at a person’s home by specialized nurses. When will it be available at my doctor? Now that Aduhelm is approved, the manufacturer will need some time to ramp up large-scale production and arrange for nationwide — even global — distribution. What are the side effects? In clinical trials, the most common side effects were ARIA-E (abnormal brain changes associated with anti-amyloid treatments — most often swelling in the brain — that are spotted with neuroimaging techniques like MRI), headache, ARIA-H (micro hemorrhage/superficial siderosis) and fall. Can I take this drug with my other medications/supplements? When considering any treatment, including aducanumab, it is important to have a conversation with your health care provider to ensure you are a candidate for the treatment. This includes taking into account other health conditions, medications or supplements. How will COVID-19 impact my ability to get this treatment? Throughout the pandemic, our health care systems have adapted. People have continued to receive treatments, including infusions such as chemotherapy, with extra precautions such as social distancing and wearing a mask. Talk to your doctor to find out if aducanumab is right for you or a loved one, and discuss a plan to identify extra precautions for COVID safety. It’s a new day in the fight to end Alzheimer’s Approval of aducanumab is a milestone in the treatment of Alzheimer’s. Current progress in science is significant, and we expect this will be the first of a number of treatments to come. Learn more. 29
30 Publizr Home